Avidity Biosciences

San Diego, United States Founded: 2012 • Age: 14 yrs Acquired By Novartis
Antibody-siRNA complexes are developed for cancer treatment.
Request Access

About Avidity Biosciences

Avidity Biosciences is a company based in San Diego (United States) founded in 2012 was acquired by Novartis in October 2025.. Avidity Biosciences has raised $142.54 million across 7 funding rounds from investors including Lilly, Novartis and ARE. The company has 391 employees as of December 31, 2024. Avidity Biosciences offers products and services including AOC Platform and Pipeline for DM1. Avidity Biosciences operates in a competitive market with competitors including Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.

  • Headquarter San Diego, United States
  • Employees 391 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Avidity Biosciences, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $10.9 M
    13.99
    as on Dec 31, 2024
  • Net Profit
    $-322.3 M
    -51.87
    as on Dec 31, 2024
  • EBITDA
    $-376.16 M
    -61.1
    as on Dec 31, 2024
  • Total Equity Funding
    $142.54 M (USD)

    in 7 rounds

  • Latest Funding Round
    $400.21 M (USD), Post-IPO

    Mar 04, 2024

  • Investors
    Lilly

    & 18 more

  • Employee Count
    391

    as on Dec 31, 2024

  • Acquired by
    Novartis

    (Oct 27, 2025)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Avidity Biosciences

Avidity Biosciences is a publicly listed company on the NASDAQ with ticker symbol RNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: RNA . Sector: Health technology · USA

Products & Services of Avidity Biosciences

Avidity Biosciences offers a comprehensive portfolio of products and services, including AOC Platform and Pipeline for DM1. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform combines antibodies and oligonucleotides for targeted disease treatment.

Develops treatments for myotonic dystrophy type 1 and related conditions.

People of Avidity Biosciences
Headcount 50-200
Employee Profiles 211
Board Members and Advisors 6
Employee Profiles
People
Michael Cochran
Director, Chemistry
People
Theresa F.
Senior Manager Regulatory Affairs
People
John W. Wallen III
General Counsel
People
Jennifer Perkins
Senior Executive Assistant

Unlock access to complete

Board Members and Advisors
people
Tamar Thompson
Board Member
people
Troy Wilson
Chairman & Co-Founder

Unlock access to complete

Funding Insights of Avidity Biosciences

Avidity Biosciences has successfully raised a total of $142.54M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $400.21 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Post-IPO — $400.2M
  • First Round

    (14 Feb 2014)

  • Investors Count 18
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2024 Amount Post-IPO - Avidity Biosciences Valuation

investors

Nov, 2019 Amount Series C - Avidity Biosciences Valuation RTW Investments
Apr, 2019 Amount Series B - Avidity Biosciences Valuation Lilly
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Avidity Biosciences

Avidity Biosciences has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Novartis and ARE. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Life Sciences focused VC firm investing in the US
Founded Year Domain Location
Health-tech companies are targeted for venture capital investments.
Founded Year Domain Location
Private equity fund focused on the biotechnology sector
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Avidity Biosciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Avidity Biosciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Avidity Biosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Avidity Biosciences

Avidity Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Avidity Biosciences

Frequently Asked Questions about Avidity Biosciences

When was Avidity Biosciences founded?

Avidity Biosciences was founded in 2012 and raised its 1st funding round 2 years after it was founded.

Where is Avidity Biosciences located?

Avidity Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Who is the current CEO of Avidity Biosciences?

Sarah Boyce is the current CEO of Avidity Biosciences.

Is Avidity Biosciences a funded company?

Avidity Biosciences is a funded company, having raised a total of $142.54M across 7 funding rounds to date. The company's 1st funding round was a Series B of $15M, raised on Feb 14, 2014.

How many employees does Avidity Biosciences have?

As of Dec 31, 2024, the latest employee count at Avidity Biosciences is 391.

What is the annual revenue of Avidity Biosciences?

Annual revenue of Avidity Biosciences is $10.9M as on Dec 31, 2024.

What does Avidity Biosciences do?

Avidity Biosciences was founded in 2012 in San Diego, United States, within the biotechnology sector focused on oncology. Antibody-siRNA complexes, known as ARCs, are advanced to combine elements of antibody-drug conjugates and nucleic acid therapeutics. Targeted polymeric nanoparticles encapsulating siRNA payloads are created for delivery to specific tumor types. These nanoparticles are decorated with antibodies, proteins, peptides, or small molecules to enable binding to extracellular receptors and promote cellular uptake.

Who are the top competitors of Avidity Biosciences?

Avidity Biosciences's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does Avidity Biosciences offer?

Avidity Biosciences offers AOC Platform and Pipeline for DM1.

Is Avidity Biosciences publicly traded?

Yes, Avidity Biosciences is publicly traded on NASDAQ under the ticker symbol RNA.

Who are Avidity Biosciences's investors?

Avidity Biosciences has 19 investors. Key investors include Lilly, Novartis, ARE, TPG, and RTW Investments.

What is Avidity Biosciences's ticker symbol?

The ticker symbol of Avidity Biosciences is RNA on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available